Aclarion Inc. (Nasdaq: ACON, ACONW) has secured nearly $20 million in gross proceeds since Jan. 1, 2025, which fully funds its pivotal CLARITY trial. The trial is designed to demonstrate the clinical and economic value of Nociscan in spine surgery. Ryan Bond, chief strategy officer of Broomfield-based Aclarion, said, “This milestone ensures we reach the
Terumo Blood and Cell Technologies (Terumo BCT) announced today that Carter BloodCare is the first U.S. adopter of its Reveos Automated Blood Processing System and Lumia Software Platform. This implementation aims to meet the needs of Texas patients for platelets, plasma and red blood cells. Carter BloodCare, one of the largest blood centers in Texas,
Osteotec has announced an exclusive distribution agreement with Westminster-based Highridge Medical to distribute spine surgery solutions in the UK. The partnership, effective Dec. 13, 2024, combines Osteotec’s established presence in the UK with Highridge Medical’s spinal products. This move aims to strengthen Osteotec’s spine product portfolio and enhance opportunities for both patient outcomes and market
Terumo Blood and Cell Technologies (Terumo BCT) and FUJIFILM Irvine Scientific will collaborate to accelerate T cell expansion for cell therapy developers. The partnership focuses on using Fujifilm’s PRIME-XV T Cell Expansion Media in conjunction with Terumo BCT’s Quantum Flex Cell Expansion System. This collaboration aims to simplify and scale T cell expansion processes, reducing
Osteotec, a Newbury, U.K.-based manufacturer and distributor of specialized medical devices, has announced an exclusive agreement to distribute Cerapedics Inc.’s i-FACTOR bone graft portfolio in the U.K. and Ireland. This agreement expands Osteotec’s offerings, enabling healthcare professionals to access Cerapedics’ i-FACTOR Bone Graft Putty and i-FACTOR Bone Graft FLEX FR products for spine procedures. The
Terumo Blood and Cell Technologies (Terumo BCT) has announced funding support for a multi-center clinical trial aimed at reducing complications from acute chest syndrome (ACS) in adult patients with sickle cell disease (SCD). Researchers at Henri Mondor University Hospital in France will lead the trial, known as ARCAD, to evaluate the efficacy and safety of
Terumo Blood and Cell Technologies (Terumo BCT) has announced a strategic partnership with Terumo Medical Products (Hangzhou) Co. Ltd., investing in a production facility in Qiantang District, Hangzhou. This initiative aims to provide locally made medical products for the Chinese market, including devices used to collect and separate blood and cells. The launch ceremony, themed
Lakewood-based Terumo Blood and Cell Technologies (Terumo BCT) has announced the establishment of its new Global Therapy Innovations business unit. The unit aims to integrate disease expertise throughout the patient journey, from cell collections to therapy delivery, and is led by Veerle d’Haenens, general manager, Global Therapy Innovations. The initiative intends to enhance standards of
Terumo Blood and Cell Technologies (Terumo BCT) is scaling up its offerings in Latin America to promote the adoption of automated manufacturing for cell and gene therapy companies in Brazil, Colombia and Mexico. The company aims to enhance efficiency and cost-effectiveness in the manufacturing process for regional firms. Cell and gene therapies are rapidly advancing